Full-Time
Senior Performance & People Manager
Posted on 10/31/2025
Sonio
51-200 employees
AI-powered fetal ultrasound software for diagnosis
Compensation Overview
$120k - $130k/yr
Boston, MA, USA + 1 more
More locations: Paris, France
In Person
 People & HR (1) |
|---|
- Experience in strategy (start-up, consulting, etc.)
- Strong understanding of the US employment market for tech start-ups
- Strong cultural fit between impact, performance and care
- Strong empathy, ability to support & challenge in a caring and supportive way
- Strong interest in people topics, ideally some experience with communication, feedback, performance or other people framework
- Location: Boston; this role could fit someone based in Paris with a strong knowledge of the US market
- Support the executive committee in building the team and processes that will reach 2026 and onwards objectives (Revenue generation, Customer satisfaction, installation at scale)
- Define & run Sonio’s performance framework holistically
- Run the performance review cycles end-to-end
- Continuously improve the incentive system & salary grid to reward performance fairly across the team
- Ensure metrics used to follow performance are robust
- Coach, Train & Support managers to guarantee a great management experience for each employee in line with our culture of performance and care
- Own the overall training plan for the company (€100k+ budget) to ensure we have the right team & skills to address business challenges
- As the first US-hire in the HR team, focus specifically on the US, ensuring we can provide a best-in-class employee experience. Also, you’ll support some operational tasks in the US
- You'll work with all teams and have a lot of exposure to the CEO (also based in the Boston office), COO and other excom members
Sonio develops AI-based fetal ultrasound software to assist clinicians in analyzing prenatal ultrasound images and diagnosing congenital malformations. The software blends ultrasound semiology with patient medical history, genetic and biological data to provide decision support and guide physicians toward the most likely diagnosis, while also assisting sonographers during prenatal screening scans. It integrates into clinical workflows to deliver timely insights for healthcare providers and support for mothers and their babies. Unlike tools that rely on a single data type, Sonio combines multiple sources of information to help practitioners interpret scans more accurately and efficiently. The company’s goal is to improve the accuracy and speed of fetal anomaly screening and enhance maternal-fetal health outcomes.
Company Size
51-200
Company Stage
Acquired
Total Funding
$112.2M
Headquarters
Paris, France
Founded
2020
Simplify's Take
What believers are saying
- Samsung's €86M acquisition expands distribution via global ultrasound networks.
- FDA clearance of Detect v3 and CE Mark enable U.S. and EU market growth.
- Pediatrix contract deploys Sonio in 100+ U.S. clinics since February 2024.
What critics are saying
- GE HealthCare's Viewpoint 6.1 captures 25% larger MFM share via EMR integrations.
- FDA audit reveals Detect v3 underperforms in high-BMI cases, triggers recall.
- Philips EPIQ CVx locks 40% ultrasound base with rival voice transcription.
What makes Sonio unique
- Sonio Detect v3 detects 14 T1 views at 88.6% sensitivity and 40 T2/T3 views at 90.1%.
- Sonio Voice enables real-time AI voice transcription for OB-GYN ultrasound reporting.
- Sonio combines patient history, genetics, and ultrasound for malformation diagnosis.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Flexible Work Hours
Company News
Sonio announces FDA clearance of the 3rd version of Sonio Detect. Sonio SAS is thrilled to share that its revolutionary AI-powered solution, the third version of Sonio Detect, has received FDA 510(k) clearance. Sonio Detect is designed to ensure high-quality exams by automatically detecting views and anatomical structures, and verifying quality criteria of ultrasound images. Efficient workflows, quality assurance and anomaly detection have been its top priorities since founding Sonio. Today, Sonio SAS is reenforcing its commitment to Quality Assurance with the FDA clearance of the third version of Sonio Detect, which expanded the scope of its AI-powered image evaluation. What's new in Detect v3. Sonio Detect v3 introduces several new capabilities: * Expanded scope of automatically detected views: it detects 14 T1 views with 88.6% sensitivity and 98.1% specificity; and 40 T2/T3 views with 90.1% sensitivity and 99.3% specificity * Expanded scope of ISUOG/AIUM guidelines % coverage: Detect v3 now covers up to 65% of ISUOG and 65% AIUM T2/T3 detailed exam protocols without manual annotation, with a target roadmap set to cover 100% by next release * Expanded scope of automatically detected structures: while maintaining performance in detecting Brain and Thorax/Heart structures at T2/T3, scope has expanded to include 58 anatomical structures (15 at T1 and 43 at T2/T3) over various anatomical regions: brain, face, profile, thorax, heart, and placenta * Automatic localization of specific structures on the image to provide users more context on what AI detected * As with with Detect v2, Detect v3 continues to automatically detect placenta location and fetus sex The integration of Sonio Detect V3 into its platform is currently underway. While Sonio SAS is excited to bring these enhanced capabilities to its users in the coming months, Sonio SAS is committed to ensuring a seamless rollout and will share specific timing as soon as it's confirmed. Empowering quality care through ai-powered ultrasound. Sonio is an advanced AI-powered ultrasound reporting solution that standardizes fetal ultrasound quality through AIUM or site-specific templates, automated reporting, and intelligent quality checks. With customizable protocols, finding-based reporting templates, and clinical decision support features, the platform empowers healthcare providers to deliver consistent, high-quality care. Sonio gives both physicians and sonographers confidence in their daily practice while supporting liability and risk management. Sonio is designed to support practices in efforts to reduce avoidable errors, align exams with protocols, improve report coherence for smoother review, and reduce inter-sonographer variability. By automating repetitive tasks such as data entry and report generation, the solution is built to streamline workflows and free up valuable time for patient care, while providing objective signals to upskill sonographers over time. Its ambition is to bridge the gap between structure, view detection, and anomaly detection to improve both screening and diagnosis in the near future. Ready to improve your patient care? Contact Sonio SAS and discover Sonio, the next-generation of Prenatal Ultrasounds.
Sonio launches new ai-powered product suite to enhance maternal healthcare in the U.S.
Established in 2020 to enhance women and children's health globally through medical advancements, Sonio has developed IT solutions and AI assistant features for obstetrics and gynecology ultrasound that assist medical professionals in the evaluation and documentation of ultrasound exams.
Sonio showcases AI innovations at SMFM Annual Pregnancy Meeting 2025.
- Sonio, a global provider of AI-driven medical technology innovation announced the launch of Sonio Voice, a cutting-edge voice recognition solution designed to revolutionize ultrasound reporting in obstetrics and gynecology (OB-GYN) practices.